Observia

[Beyond DTx] As healthcare actors, we are incentivized to always reach for the latest innovation, the newest way of working. But is this the right way to go? The question is particularly relevant regarding Digital Therapeutics, that appear to be the next big thing in the industry.   Between cost management, regulatory compliance, clinical validation and long development cycles, developing a DTx pauses a wide range of operational challenges.   At the same time, they offer measurable clinical outcomes and a new way to treat patients.   So, are they worth the effort, in a healthcare world where budgets are tighter and tighter and time a valuable resource? Do DTx offer the best ROI of digital health?   Let’s look at the bigger picture together in our latest position paper.  Access it through this link: https://lnkd.in/gnRnJh25 What are your views on the opportunity of DTx development?

[Perspectives] Emerging Markets: The Next Big Opportunity for Pharma.   With rising healthcare demand and rapid economic growth, emerging markets present a huge opportunity for pharmaceutical companies. But success in these regions requires more than just market access—it demands a patient-centric approach that ensures treatment initiation, adherence, and long-term impact.   So, how can pharma companies drive sustainable growth while enhancing their reputation and corporate responsibility?   Here are 3 key success factors we have identified, having launched solutions in countries such as Indonesia, Algeria or India.   1. Strategic Expansion: These markets offer high growth potential for premium treatments, but require tailored strategies to address affordability and patient engagement. 2. CSR: Investing in patient support programs builds trust with patients, HCPs, and governments, reinforcing pharma’s role as a healthcare partner. 3. Competitive Advantage: Companies that integrate financial solutions, education, and digital tools into their patient strategies will improve adherence and drive long-term brand loyalty.   A strong patient strategy is the key to unlocking this potential. Download our white paper to explore how pharma companies can succeed in emerging markets → https://lnkd.in/enpFajHj

[Clinical trials] Observia is thrilled to share that Clinical ink is the exclusive provider of the SPUR behavioral diagnostic tool for clinical trials. We are excited to see this unique adherence solution become a valuable asset to improve patient retention and preserve study power. Kevin Dolgin, Observia's Head of R&D and primary developer of SPUR, says: "Clinical ink is one of the most forward-thinking providers of services around clinical trials and their commitment to bring behavioral science into the world of clinical science is proof of this. I strongly believe that thanks to Clinical ink’s initiative, trials will now be more efficient, more precise, and far more patient-centric. At Observia, we look forward to continuing to support Clinical ink with associated behavioral science input while we continue to support our commercial customers post launch". Explore the power of the tool and its scientific robustness with the dedicated SPUR website: https://lnkd.in/evrnQjxs

[Connected Patients] Diabetes is one of the most widespread chronic diseases in the world, and also one with a complex and strict treatment, from frequent insulin shots to a precise diet. That’s why adherence has such a great part to play in its management.   To improve patients’ outcomes and support healthcare professionals, Observia developed for one of its clients a hybrid personalized coaching program, dedicated to patients living with type 2 diabetes in Indonesia.   Powered by SPUR and implemented in a local call-center, this program helped nurses give the right information to patients, according to their needs and concerns.   Better informed, patients became more engaged in their care plan and more adherent to their treatment. Discover all the figures of this project in our new series, Connected Patients.

[B.Corp] Discover how Governance drives our mission: Chapter 1 of our B Corp journey! In healthcare, governance ensures patient interests remain at the heart of business decisions.   We believe that strong governance isn’t just about policies—it’s about creating a foundation for ethical leadership and trust across every decision we make.   Our Strength: Ethics and transparency are deeply embedded in how Observia operates. These values guide us in building meaningful relationships with all stakeholders, ensuring accountability at every level.   Our Area of Work: To truly embody our purpose, we’re working on articulating our mission not just in our solutions but every facet of our organization. This means ensuring that all teams—operational and support alike—align with our shared values and vision. Governance isn’t static; it’s a living commitment to doing what’s right, every step of the way. In the next post, we will explore how this governance approach impacts our relationships with Workers.   The word of our B.Leader, Sandrine Piotelat: 

[Journée Mondiale contre le Cancer] Unis par l’Unique : quelle devise forte pour la campagne 2025 de la Journée mondiale contre le cancer ! Cette nouvelle campagne place les personnes au centre des soins et explore de nouvelles façons de faire la différence.   L’Union Internationale contre le Cancer porte ainsi l’idée qu’une approche centrée sur la personne, intégrant pleinement les besoins uniques de chacun, avec compassion et empathie, conduit aux meilleurs résultats de santé. Nous ne pouvons que soutenir cette vision. Au service des patients chroniques et de leurs professionnels de santé, Observia travaille depuis plus de 10 ans à une prise en charge globale du cancer, notamment en accompagnant les pharmaciens d’officine dans la réalisation de leurs entretiens pharmaceutiques pour les anti cancéreux oraux (ACO). Intégré à la plateforme Observia depuis 2021, le module ACO permet aux pharmaciens d’accompagner les patients dans leur vie quotidienne avec le cancer, pour qu’ils aient toutes les clés de compréhension et de gestion de leur traitement. Etape clé de la gestion du cancer hors de l’hôpital, la délivrance d’ACO par le pharmacien et l’accompagnement en entretien pharmaceutique vise à adapter les traitements au quotidien des patients, pour qu’ils conservent la meilleure qualité de vie possible. Chez Observia, nous sommes persuadés qu’un accompagnement adapté et centré sur le parcours de vie peut faire la différence. Engageons-nous ensemble pour soutenir les personnes atteintes d’un cancer ! #UnisParLUnique

[Rare disease] When it comes to rare disease, patient support is more crucial than ever, as individuals can face scarceness of information resources and uncertainty. To help them, life science companies need to understand their condition to offer the right support.   For one of our clients, we conceived a holistic patient support program (PSP) that answers both challenges, for patients suffering from a rare skin condition including: 👉 A digital Patient Reported Outcome (ePRO) feature for the collection of anonymized real-life data + questionnaires about quality of life and disease impact 👉 9 features for patients, including an information center, gamified challenges and a self-symptom tracker   The patient’s experience is fully personalized through Observia’s in-house suite of products SPUR, d.tells and OPC, creating a unique program adapted to their individual needs.   Click the link below to access all the details 👇 https://lnkd.in/eWcVCNHz

[B.Corp] We are happy to share that Observia is officially on the path to becoming a Certified B Corporation!   With the guidance and expertise of our B.Leader Sandrine Piotelat, we are navigating this transformative journey to align our business more deeply with social and environmental impact.   For us, B Corp is not about following a trend—it’s a reflection of our conviction that businesses have a critical role to play in building a more sustainable and equitable world. This commitment is at the very heart of our strategy.   We firmly believe that embracing the principles of sustainability, transparency, and stakeholder accountability isn’t just the right thing to do—it’s a powerful business asset that will drive long-term value and resilience for Observia and our partners. As of 2024, out of the 9,000 companies worldwide that hold the B Corp certification, only 200 belong to the healthcare sector—a mere 2%. Yet another reason for us to be excited for this new challenge: we hope to inspire our clients and partners to follow us on this path!   In the next weeks, we will be sharing our advancement on the 5 pillars that contribute to a company’s overall B Impact Assessment Score: Governance, Customers, Community, Workers and Environment. Stay tuned! 

[Congrès] C’est un rendez-vous que l’on ne rate jamais : les JADE & ITD, Journées Antillaises de Diabétologie et Endocrinologie ! Au-delà d’une opportunité unique de profiter du soleil guadeloupéen, il s’agit surtout de rencontrer et d’échanger autour des dernières avancées en diabétologie et endocrinologie avec des soignants de métropole, des DOM-TOM, de Belgique ou encore du Canada. Cette année nous retrouvons notamment le Dr. Saïd Bekka, partenaire d’Observia pour une étude menée au sein de l’Institut de Diabétologie et Nutrition du Centre - LNA Santé (IDNC). Cette étude doit permettre de répondre à une question clé : La personnalisation de la prise en charge éducative des patients induit-elle des changements de comportement de santé plus bénéfiques et durables ? Merci au Dr. Said Bekka pour son soutien à une meilleure compréhension des patients !

[Hello 2025] A new year always sparks reflection on what will be coming in the coming months. Here's a glimpse at what Observia has in mind... Healthcare is changing, and digital transformation is putting patients at the heart of care. Technology becomes a way to make care more personal, accessible and impactful; to build a new relationship between patients and their care journey. With tools like AI-powered analytics, healthcare providers can intervene at the right time. Mobile apps and patient portals make it easier for people to stay informed and engaged. Beyond physical health, there’s a growing focus on mental well-being, driven by behavioral and social factors. Digital tools are now breaking down barriers to a holistic approach of the patient. We’re proud to support these changes and help shape a future where healthcare works better for everyone. In 2025, our wish is to keep building a patient-first, innovative future—with you. Happy New Year from our whole team!